Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 173

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 173
---
-IFRS) | 39,676 | 37,651 | +5.4%  |

(a) Figures for 2023 and 2022 have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. 1/ Net sales by operating segment Our net sales comprise the net sales generated by our Biopharma segment.

| (€ million)(a)    |   2023 |   2022 | Change on areported basis | Change at constantexchange rates |
| Biopharma segment | 37,817 | 37,651 | +0.4%                     | +5.4%                            |
| Total net sales   | 37,817 | 37,651 | +0.4%                     | +5.4%                            |

(a) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.

| SANOFIFORM 20-F2024 | 81 |

| PART I                                               |
| ITEM 5. Operating and Financial Review and Prospects |

2/ Net sales by medicine, vaccine and geography – 2023 compared with 2022

| (€ million)                                 | Total sales | Change(CER) | Change(reported) | UnitedStates | Change(CER) | Europe | Change(CER) | Rest ofthe world | Change(CER) |
| Immunology                                  |             |             |                  |              |             |        |             |                  |             |
| Dupixent                                    |      10,715 | +34.0%      | +29.2%           |        8,145 | +32.6%      |  1,224 | +30.9%      |            1,346 | +46.2%      |
| Kevzara                                     |         357 | +9.7%       | +5.3%            |          195 | +8.6%       |    115 | +8.5%       |               47 | +17.0%      |
| Rare diseases                               |             |             |                  |              |             |        |             |                  |             |
| Fabrazyme                                   |         990 | +11.9%      | +6.3%            |          503 | +9.8%       |    241 | +6.1%